THG, MS, CG, and XH are employees and shareholders of Eli Lilly. HM, SP, CB and EC are employees and in some cases stockholders of Clarivate Analytics. Clarivate Analytics provides consultancy to various pharmaceutical and biotechnology companies, including Eli Lilly, the funder of this research. AKG has served as a speaker for Lilly, Novo Nordisk, and Currax and a consultant to Lilly, Novo Nordisk, Currax, and Epitomee. HEB's research site institution has received research grants from 89Bio, Abbvie, Allergan, Alon Medtech/Epitomee, Aligos, Altimmune, Amgen, Anji Pharma, AstraZeneca, Bioage, Biohaven, Bionime, Boehringer Ingelheim, Carmot, Chorus/Bioage, Eli Lilly, Esperion, Evidera, Fractyl, GlaxoSmithKline, Graviton, HighTide, Home Access, Horizon, Ionis, Kallyope, LG-Chem, Marea, Madrigal, Marea, Merck, Mineralys, New Amsterdam, Novartis, NovoNordisk, Pfizer, Regeneron, Satsuma, Selecta, Shionogi, Skye/Birdrock, Tern, TIMI, Veru, Viking, Vivus, Zomagen. HEB has served as a consultant (e.g., executive/national committee member and/or protocol/drug development advisor) for 89Bio, Altimmune, Amgen, Boehringer Ingelheim, Eva Pharma, Kiniksa, HighTide, Lilly, Nestle, Novo Nordisk, Regeneron, Rivus, Veru, Zomagen, ZyVersa, and serves as an editor on the Obesity Pillars board.
PubMed
